Cubist Systematic Strategies, LLC Tango Therapeutics, Inc. Transaction History

Cubist Systematic Strategies, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$6.52 - $12.01 $660,684 - $1.22 Million	101,332 New	101,332 $1 Million
Q1 2023 May 15, 2023	BUY	$3.76 - $8.06 $63,145 - $135,359	16,794 New	16,794 $66,000
Q3 2022 Nov 14, 2022	SELL	$3.25 - $5.46 $195,958 - $329,210	-60,295 Reduced 85.06%	10,594 $38,000
Q2 2022 Aug 15, 2022	BUY	$3.86 - $8.01 $50,214 - $104,202	13,009 Added 22.48%	70,889 $321,000
Q1 2022 May 16, 2022	BUY	$7.01 - $10.94 $405,738 - $633,207	57,880 New	57,880 $439,000
Q4 2021 Feb 14, 2022	SELL	$9.55 - $14.29 $150,813 - $225,667	-15,792 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$9.56 - $17.3 $150,971 - $273,201	15,792 New	15,792 $204,000

123

91.7M

3.1K

1.5K

Ticker TNGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 88,067,296
Market Cap $268M
Description
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...

Get notified when there are updates to the investment portfolio of Cubist Systematic Strategies, LLC, based on Form 13F filings with the SEC.

Stay updated on Cubist Systematic Strategies, LLC with notifications on news.